It is logical to expect that large-volume leukapheresis may be able to collect adequate numbers of PBSC with fewer procedures. To date, there is no agreement on the optimal volume of leukapheresis. Therefore, in this study we compared 8 l volume with 12 l and assessed whether a 50% increase in the blood volume processed would decrease the number of leukaphereses each patient needed to collect у2. 
Summary:
It is logical to expect that large-volume leukapheresis may be able to collect adequate numbers of PBSC with fewer procedures. To date, there is no agreement on the optimal volume of leukapheresis. Therefore, in this study we compared 8 l volume with 12 l and assessed whether a 50% increase in the blood volume processed would decrease the number of leukaphereses each patient needed to collect у2.5 ؋ 10 6 CD34 ؉ cells/kg in normal mobilizers. PBSC mobilization was done with cyclophosphamide etoposide followed by rhG-CSF in all patients. Forty patients were randomized to undergo 8 l leukaphereses (n ‫؍‬ 20 patients) or 12 l leukaphereses (n ‫؍‬ 20). The median numbers of leukaphereses required in order to collect у2. 5 Two important reasons for their use are the faster hematopoietic recovery of mobilized PBSC compared with steadystate bone marrow support and the ability to collect PBSCs as an outpatient procedure. [1] [2] [3] The best way to mobilize and collect PBSCs is yet to be defined. It is logical to expect that large-volume leukapheresis (LVL) may be able to collect adequate numbers of PBSCs with fewer procedures. Therefore, LVL has been proposed as a way to collect adequate numbers of PBSC using fewer collection procedures. 4, 5 Such an approach may be beneficial and costeffective to the patient and hospital. Schwarer et al 6 compared standard volume with large volume in patients with a variety of malignant hematologic diseases undergoing PBSC mobilization and reported no difference between two groups regarding numbers of aphereses and collected CD34 ؉ cells. 6 Based on the limited data available on this issue in the literature, we decided to conduct a randomized comparison of leukapheresis volume 8 l with 12 l to evaluate whether or not the larger volume would decrease the number of leukaphereses by increasing the numbers of CD34 ϩ cells/kg collected.
Patients and methods
The purpose of this study was to evaluate the number of leukaphereses at each collection volume, 8 l or 12 l, required to collect Ͼ2.5 ϫ 10 6 CD34 ϩ cells/kg body weight of the patient. Forty patients were randomly assigned to either a 8 l (n ϭ 20 patients) or 12 l (n ϭ 20 patients) leukapheresis volume. Collections of the assigned volume were to be continued until Ͼ2.5 ϫ 10 6 CD34 ϩ cells/kg were collected. If five collections had been performed and Ͻ1 ϫ 10 6 CD34 ϩ cells/kg had been collected, a BM harvest would be performed to supplement the stem cell number.
Patients
Between November 1999 and October 2001, 40 patients meeting protocol eligibility criteria for treatment with highdose chemotherapy requiring PBSC transfusion received cyclophosphamide (CY), etoposide and rhG-CSF for mobilization of PBSCs. 1 Patients characteristics are listed in Table 1 . Patients were eligible for PBSC mobilization and harvest if they had Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2, were aged р65, and had evidence of adequate hepatic, renal and cardiac function.
Informed consent
Oral and written informed consent for PBSC collection was obtained from all patients or their guardians. Oaks, CA, USA) 16 g/kg/day i.v. twice daily was started the day after completion of chemotherapy and continued until the last day of apheresis. Patients received antibiotic prophylaxis with ciprofloxacin 750 mg orally twice per day when the WBC count was less than 0.5 ϫ 10 9 /l. Apheresis was performed by using Fenwall CS3000ϩ (Baxter Health Care System, Deerfield, IL, USA) and started as soon as WBC counts reach у2 ϫ 10 9 /l following a nadir.
Leukapheresis procedure
All procedures were performed with a Baxter CS3000ϩ by nursing staff and procedures were run at 55 ml/min whole blood flow rate with acid citrate dextrose-A (ACD-A) formulation as the anticoagulant. The interface was set at 20 at commencement of the procedure and adjusted up or down by the operator to obtain the appropriate collection consistency as determined by the color of the componentrich plasma line. A draw line was usually obtained peripherally, and the return line was a Hickman catheter. All procedures gave a final leukapheresis product volume of 220 ml; this volume was independent of the volume of patient's peripheral blood processed during the procedure (8 l or 12 l).
Quantitation of CD34
ϩ cells
Circulating peripheral blood CD34 ϩ cell counts prior to apheresis and collected CD34 ϩ cell counts in the apheresis product after each collection were analyzed using flow cytometry. Erythrocytes were removed from samples of cells obtained before cryopreservation or after thawing and serial dilution by hypotonic lysis using ammonium chloride. The cells were then stained with a fluorescein isothiocyanate or phycoerythin-conjugated CD34 antibody (8G12; Becton Dickinson, San Jose, CA, USA) or an irrel-evant isotype control, washed and counterstained with propidium iodide (PBI; Becton Dickinson) or 7-aminoactinomycin D (7AAD; Sigma Chemical, St Louis, MO, USA). After an additional wash and within 2 h of staining, the proportions of viable (PI or 7AAD excluding) cells, mononuclear cells and CD34 ϩ cells in the fresh and thawed specimens were determined by flow cytometric analysis (FACScan, Becton Dickinson). CD34 ϩ cells showed fluorescence of Ͼ99.8% of isotype control-stained cells. The quantities of these cell populations in each product before and after freezing were determined. 7 
Statistics
The Mann-Whitney U test and a two sample, two-tailed ttest were used to test for differences in collection numbers and cell yields between the two treatment arms. Student's t-test was also used to compare body weight and age of the patients in both groups. Gender, disease type and previous chemotherapies were compared with chi-square analyses.
Results

Patient details
Twenty patients were randomized to a 8 l leukapheresis volume and 20 patients to a 12 l leukapheresis volume. The groups were evenly matched for clinical parameters (Table  1) . Median numbers of WBC and platelet counts on the first day of apheresis in patients processed with 8 l and 12 l were 6.67 ϫ 10 9 /l (range 2.49-13.60), 43.85 ϫ 10 9 /l (10.76-117.000) and 5.7 ϫ 10 9 /l (range 2.10-14.18), 48.4 ϫ 10 9 /l (18.21-131.000) (P Ͼ 0.05), respectively ( Table 1) .
Number of leukapheresis per patient
Total numbers of leukaphereses required to collect у2.5 ϫ 10 6 CD34 ϩ cells/kg in patients processed with 8 l and 12 l were 32 and 30, respectively ( Table 2 ). Eleven of 20 (55%) patients in the 8 l group and 13 of 20 in the 12 l group (65%) reached the minimal requirement of CD34 ϩ cells (у2.5 ϫ 10 6 /kg) in one collection (P ϭ 0.52) ( Table 2 ). There was no difference between the two groups regarding the number of leukaphereses performed per patient. The median numbers of leukaphereses performed per patient required to collect у2.5 ϫ 10 6 CD34 ϩ cells/kg in 8 l and P value ϭ 0.52.
Bone Marrow Transplantation
12 l groups were 1 (range 1-5) and 1 (1-4), respectively (P ϭ 0.50) ( Table 3) .
Cells collected per patient
The total numbers of TNCs collected per kilogram of patient body weight (P Ͻ 0.001) and TMNCs collected per kilogram of patient body weight (P Ͻ 0.001) were greater in the 12 l collection group, whereas there was no statistical difference in CD34 ϩ cell numbers collected per patient (P ϭ 0.85) ( Table 3) .
Cells collected per leukapheresis
The per leukapheresis number of TNCs collected per kilogram of patient body weight (P ϭ 0.001) and MNCs collected per kilogram of patient body weight (P Ͻ 0.001) were greater in the 12 l collection group, whereas there was no statistical difference in CD34 ϩ cell numbers per kilogram of patient body weight collected (P ϭ 0.90) ( Table 4) .
Discussion
The convenience and cost of PBSC collection are influenced by the number of leukaphereses required to collect a target number of hematopoietic progenitors to support one or more cycles of dose-intensive cytotoxic chemotherapy. One difficulty in assessing the efficiency of a leukapheresis procedure to collect PBSC is the wide variability among patients in the concentration of PBSCs as a consequence of underlying disease and the extent of prior cytotoxic therapy. Some studies have shown that CD34 ϩ cells are mobilized into the peripheral blood during LVL. 8, 9 On the basis of those observations, some authors have suggested that processing larger volumes of peripheral blood during each leukapheresis procedure may collect a larger number of CD34 ϩ cells than processing of one to two patient blood volumes. 5, 6, 8, 9 LVL take a proportionally longer time for the patient and are more likely to be associated with adverse events, such as citrate reactions, intravenous access difficulties, patient discomfort, anemia and thrombocytopenia. Kobbe et al 5 investigated the effect of LVL on the collected stem cell yields of allogeneic donors and showed that LVL is safe and effective in maximizing the total number of harvested progenitor cells in healthy individuals. In that study, authors strongly recommended large volume processing in the poor mobilizers, who are characterized by low levels of circulating CD34 ϩ cells but LVL seemed to be of limited clinical value in individuals with very high (Ͼ80-100/l) peripheral CD34 ϩ cell counts. 5 Eight liter, 10 l and 12 l leukaphereses were the most frequently processed blood volumes at our institution. Initially, we compared the 8 l volume with 10 l to assess whether or not the larger blood volume processed would increase the number of CD34 ϩ cells in each collection in normal mobilizers. 10 In that study, there was no difference between the two groups regarding number of aphereses and collected CD34 ϩ cells. 10 Because of the low volume difference between 8 l and 10 l, and to see whether our previous observation is confirmed or not, we decided to compare the 8 l processed with the larger 12 l processed volume in a randomized trial to assess whether or not a 50% increase in the blood volume processed would increase the number of CD34 ϩ cells in each collection and thus decrease the average number of leukaphereses needed to reach the goal of у2.5 ϫ 10 6 CD34 ϩ cells/kg patient body weight. However, the 12 l collection volume also did not decrease the number of leukaphereses needed to reach the prescribed CD34 ϩ cell number ( Table 2 ). The median number of leukaphereses needed in order to collect у2.5 ϫ 10 6 CD34 ϩ cells/kg was 1 for the 8 l and 12 l groups (P ϭ 0.50), and there were no differences in the proportion of patients who required one, two or three leukaphereses to reach the minimal required number of CD34 ϩ cells. Fifty-five and 65% of patients in one collection and 30 and 25% of patients in two collections reached the target number of у2.5 ϫ 10 6
CD34
ϩ cells/kg in 8 l and 12 l groups, respectively (P ϭ 0.52) ( Table 2) .
In this study, overall and per leukapheresis, the patients undergoing the 12 l procedure had more TNC and MNC collected, although this did not translate into more CD34 ϩ cells collected. The numbers of CD34 ϩ cells collected overall and per leukapheresis were not significantly different between the two groups. This may be related to release kinetics of CD34 ϩ cells into peripheral blood which may be partially or completely independent of processed volume. It is also plausible to think that release kinetics of TNC and MNCs may be different from that of CD34 ϩ cells. It has to be noted that this study was conducted in normal mobilizers. Therefore, the results do not imply that in the poor mobilizer setting, large volume procedure is useless.
In summary, in the current study, the larger leukapheresis volume of 12 l provided no advantages over the 8 l leukapheresis volume in normal mobilizers. There was no decrease in the absolute number of leukapheresis procedures performed for patients having the larger, 12 l, blood volume processed when compared with patients having the 8 l blood volume processed. An adequate number of CD34 ϩ cells was collected in a median of one procedure with both leukapheresis volumes. In fact, the use of the larger leukapheresis volume had the disadvantage of adding 60 min to the time the patient was on the machine. 
